Navigation Links
Design of a new system that improves hearing in patients who carry a cochlear implant
Date:3/4/2008

ssor in the implant should be specifically programmed for each patient. In order to do so, a programmer performs some subjective tests on the patient. Carrying out this task can get especially hard with children or non-cooperative patients, whose interaction with the programmer is limited or void. So, the search for an objective measurement which provides the automatic programming for the cochlear implant is one of the main research lines opened by the manufacturers. The Compound Action Potential is included in this aim.

The author of this work, Isaac Manuel lvarez Ruiz, states that the major difficulty in the recording and processing of the Compound Action Potential is the stimulation device, insomuch that the stimulation signal interferes in time and frequency with the recalled potential that is meant to be observed. In his thesis, an algorithm has been developed to allow an evaluation of the quality of a Compound Action Potential recording. This method lets us compare the most commonly used techniques in bibliography, as well as to develop new and improved techniques to reduce the stimulation device, points out the researcher.

The first task at the time of programming the cochlear implant is to decide which electrodes should be activated and subsequently, establish parameters for each one. So, this research has analyzed the relation between the Compound Action Potential and the cochlear implant voice processor programming map. We have found that the appearance of the potential generally involves the electrode connection and not vice versa. According to the parameters of each electrode, it has been found that the information provided by these potentials is insufficient for an automatic adjustment of the processor, in comparison with the results of our researches. Our results prove that the Compound Action Potential allows the establishment of parameters of each electrode regarding the average values of the patient, with acceptable uncertainty lev
'/>"/>

Contact: Isaac Manuel lvarez Ruiz
isamaru@ugr.es
34-626-186-403
Universidad de Granada
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. MSU engineering team designs innovative medical device
2. UCLA study identifies designer estrogen as potential MS drug
3. Implantable device designed to detect, stop seizures under study at MCG
4. Smith & Nephew Endoscopys KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries
5. Design Resource Extends Support for Orthopaedic and Cardiovascular Devices
6. Bullying Prevention Institute Designed to Empower Change in Schools
7. Smilebox and Lifetime Television Promote Breast Cancer Awareness With Multimedia Designs for Sending Mammogram Reminders and Celebrating Courage
8. Lafley Tells Shareholders That P&G is Designed to Grow
9. Independence Blue Cross Announces No Pay Getaway Promotion Designed to Encourage Healthy Behaviors
10. Fauquier Hospital - One of Only Five Nationwide to Receive Formal Designation as Patient-Centered Hospital
11. Regence Introduces Two New Plans Designed Especially for Small to Mid-Size Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3
...ts act together to check the perilous trend of twi...artment has suggested a cap on the// embryo, allow...el set in motion by the Human Fertilization and Em... the wrong side of 30. Further IVF clinics w...
...be efficient on animals according to researchers a...ps we can cure HIV infection. This is our hope," s...tario. Clinical trials of the vaccine are expect...e to be careful because we have done the animal, t...
...wn the risk of Alzheimer's disease by reducing inf... recent communiqué. The finding// holds a clue as...in the 1960s and 1970s are at a lesser chance of d...ties of ceasing loss of brain cells, which is a ch...
...ged that AIDS is no more restricted to just risk g...ses are added each day according to statistics wit...bted to be AIDS positive. It is alarming to note t... too has more number of infections being spread th...
... affected only by thalassemia intermedia till Febr... positive.// Initially, blood transfusion wa...rsened, she underwent blood transfusion 10 times l...c kits from the jute baron Govind Sarda's firm; Mo...
...ed by scientists in the US attacks the malaria par...he disease that has kills one million// people a y...veloped by Walter Reed Army Institute of Research ...common, reported the science portal EurekAlert. ...
Other Medicine News:Health News:Thalassemic patient is now HIV positive due to faulty Diagnostic kit… 2
(Date:12/3/2009)NEW YORK, Dec. 3 Guidepoint Global, LLC , a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects tre
(Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
(Date:12/3/2009)WILMINGTON, Del., Dec. 3 ParagonRx, a Delaware-based company specializing in pharmaceutical risk management and optimal medication use, will host a free webinar on Wednesday, Dec. 9, on the FDA,s dra
Breaking Medicine Technology:Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Natural and Organic Consumers Focus on Health and Wellness Amidst Public Health Concerns 61152 1Natural and Organic Consumers Focus on Health and Wellness Amidst Public Health Concerns 61152 2K State program will give young professionals skills to protect water resources 10693 1High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 1High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 2High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 3High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 4
...Host Conference Call at 9:00 a.m. EDT-, MONTVALE,...aq: MEMY ) today announced top-line data from the...ontrolled Phase 2a study,of MEM 1003, a neuronal L...sease. The trial enrolled 183 subjects with mild t...in the United States and included monotherapy,subj...
...N.J. and NEW YORK, Oct. 12 Daiichi Sankyo,Inc. an...d today that they,have signed a contract for a co-...hi Sankyo,s AZOR(TM), a fixed combination of two,a...odipine and the,angiotensin receptor blocker, olme... letter of intent for the co-promotion agreement o...
Other Medicine Technology:Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 2Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 4Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 2Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 3Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 4
Microalbumin Linearity Control
Total IgE Control
Lyophilized Lipid Control
High-sensitive CRP Control
Medicine Products: